Literature DB >> 31686095

Comparing the Standard and Electronic Versions of the Alzheimer's Disease Assessment Scale - Cognitive Subscale: A Validation Study.

T M Solomon1, J M Barbone, H T Feaster, D S Miller, G B deBros, C A Murphy, D Michalczuk.   

Abstract

The Alzheimer's Disease Assessment Scale (ADAS-Cog) has become the de facto gold-standard for assessing the efficacy of putative anti-dementia treatments. There has been an increasing interest in providing greater standardization, automation, and administration consistency to the scale. Recently, electronic versions of the ADAS-Cog (eADAS-Cog) have been utilized in clinical trials and demonstrated significant reductions in frequency of rater error as compared to paper. In order to establish validity of the electronic version (eADAS-Cog), 20 subjects who had received a diagnosis of probable Alzheimer's disease (AD) at a private US Memory Clinic completed a single-center, randomized, counterbalanced, prospective trial comparing a version of the eADAS-Cog to the standard paper scale. Interclass Correlation Coefficient on total scores and Kappa analysis on domain scores yielded high agreement (0.88 - 0.99). Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect. Overall, this study establishes adequate concurrent validity between the ADAS-Cog and eADAS-Cog among an adult population with diagnosed AD.

Entities:  

Keywords:  ADAS-cog; Alzheimer’s disease; cognition; eCOA; neuropsychology

Mesh:

Year:  2019        PMID: 31686095     DOI: 10.14283/jpad.2019.27

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  1 in total

1.  Effects of Tai Chi on Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Run Lin; Shaoyang Cui; Juan Yang; Huijun Yang; Zitong Feng; Dietlind L Wahner-Roedler; Xuan Zhou; Manisha Salinas; Molly J Mallory; Alexander Do; Sara E Bublitz; Tony Y Chon; Chunzhi Tang; Brent A Bauer; Mingzhu Xu
Journal:  Biomed Res Int       Date:  2021-04-12       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.